<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomised therapeutic trial of <z:chebi fb="0" ids="6067">13-cis-retinoic acid</z:chebi> was carried out in 70 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> having 5% or fewer marrow blast cells </plain></SENT>
<SENT sid="1" pm="."><plain>Among non-sideroblastic patients the 1-year survival in the treated group was 77%, compared with 36% in the control group </plain></SENT>
<SENT sid="2" pm="."><plain>There were too few <z:hpo ids='HP_0011420'>deaths</z:hpo> among patients with sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> to allow any effect of therapy on survival to be evaluated </plain></SENT>
</text></document>